Substance / Medication

Cyclacillin

Overview

Active Ingredient
cyclacillin
RxNorm CUI
2968

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Accuracy of leukocyte esterase and nitrite tests for diagnosing bacteriuria in older adults: a systematic review and meta-analysis.
Moragas Ana, Monfà Ramon, García-Sangenís Ana et al. · Clin Microbiol Infect · 2026
PMID: 40912457Meta-Analysis
Hyaluronic acid and chondroitin sulphate instillation in chronic bladder diseases: a meta-analysis.
Corona Giovanni, Capogrosso Paolo, Baldini Sara et al. · BJU Int · 2026
PMID: 41139434Meta-Analysis
A systematic review and meta-analysis evaluating the incidence, microbiological profile and risk factors associated with urinary tract infection after radical cystectomy.
Artiles Medina Alberto, Mínguez Ojeda César, Subiela José Daniel et al. · Urol Oncol · 2026
PMID: 41162269Meta-Analysis
Optimal duration of perioperative antibiotics in radical cystectomy and urinary diversion: a systematic review and meta-analysis.
Mohamed Tarek, Bani Irshid Baha' Aldeen, Elhashamy Hamza et al. · Langenbecks Arch Surg · 2026
PMID: 41538063Meta-AnalysisFull text (PMC)
Safety and efficacy of gepotidacin in urinary tract infection: a GRADE-assessed systematic review and meta-analysis.
Ibrahim Taha, Burhan Muhammad, Naveed Muhammad Abdullah et al. · J Antimicrob Chemother · 2026
PMID: 41549666Meta-Analysis
Does vesicoureteric reflux diagnosed following prenatal urinary tract dilatation need active management? A narrative review.
Farrugia Marie-Klaire, Montini Giovanni · J Pediatr Urol · 2025
PMID: 39406669Meta-Analysis
Effect of empiric antibiotics against Pseudomonas aeruginosa on mortality in hospitalized patients: a systematic review and meta-analysis.
Hunter Cameron J, Marhoffer Elizabeth A, Holleck Jürgen L et al. · J Antimicrob Chemother · 2025
PMID: 39656468Meta-Analysis
Vaginal antiseptic preparation at the time of hysterectomy: a systematic review and meta-analysis.
Rozycki Sarah K, Nguyen Vylan, Miroballi Natalia et al. · Am J Obstet Gynecol · 2025
PMID: 39788360Meta-Analysis

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Ciclacillin (substance)
SNOMED CT
387382002
UMLS CUI
C0010523
RxNorm CUI
2968

Clinical Data

This intervention maps to 5 entities in the Ltrl knowledge graph.

5
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.